表紙
市場調查報告書

新型冠狀病毒感染疾病 (COVID-19) 診斷檢驗的全球市場 (2020年第3季-2021年第四季):各產品類型、樣品類型、技術、終端用戶、地區/國家分析、競爭環境分析

Global COVID-19 Diagnostic Testing Market: Focus on Product Type, Sample Type, Technology, End User, Country Data (30 Countries), and Competitive Landscape - Analysis and Forecast, 3Q-2020-4Q-2021

出版商 BIS Research Inc. 商品編碼 967841
出版日期 內容資訊 英文 369 Pages
商品交期: 最快1-2個工作天內
價格
新型冠狀病毒感染疾病 (COVID-19) 診斷檢驗的全球市場 (2020年第3季-2021年第四季):各產品類型、樣品類型、技術、終端用戶、地區/國家分析、競爭環境分析 Global COVID-19 Diagnostic Testing Market: Focus on Product Type, Sample Type, Technology, End User, Country Data (30 Countries), and Competitive Landscape - Analysis and Forecast, 3Q-2020-4Q-2021
出版日期: 2020年10月20日內容資訊: 英文 369 Pages
簡介

全球新型冠狀病毒感染疾病 (COVID-19) 診斷檢驗的市場規模在預測期間內預計以23.50%的CQGR (季度年複合成長率) 發展,2021年第四季成長到356億4000萬美元的規模。COVID-19全球的感染者數增加,診斷檢驗開發的促進,技術創新,外部資金的投入,有利的法律規章方案等要素促進該市場的成長。

本報告提供全球新型冠狀病毒感染疾病 (COVID-19) 診斷檢驗的市場調查,彙整市場定義和概要,市場成長的各種影響因素分析,法律制度,產品、檢體類型、技術、終端用戶、地區/主要國家等各種區分的明細,競爭環境,主要企業簡介等資訊。

摘要整理

第1章 產品定義

第2章 調查範圍

第3章 調查手法

第4章 市場概要

第5章 產業考察

  • 概要
  • 法律上的必要條件、架構:美國
  • 法律上的必要條件、架構:歐洲
  • 法律上的必要條件、架構:亞太地區

第6章 市場動態

  • 概要
  • 影響分析
  • 促進因素
  • 阻礙因素

第7章 競爭情形

  • 主要策略、展開
  • 市場佔有率分析

第8章 市場分析、預測:各產品

  • 概要
  • 套件、化驗
  • 設備

第9章 市場分析、預測:各檢體類型

  • 鼻咽拭子
  • 中咽拭子
    • 血液檢體
    • 尿檢體
    • 其他

第10章 市場分析、預測:各技術

  • PCR
  • 等溫放大
  • 其他
    • 免疫學的檢驗
      • 側流免疫測量(LFIA)
      • 酵素免疫分析法(EIA)

第11章 市場分析、預測:各終端用戶

  • 概要
  • 醫院、醫療保健中心
  • 診斷中心、診所
  • 研究機關
  • 其他

第12章 市場分析、預測:各地區

  • 概要
  • 北美
    • 美國
    • 加拿大
    • 其他
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 荷蘭
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 台灣
    • 韓國
    • 新加坡
    • 澳洲
    • 孟加拉
    • 巴基斯坦
    • 印尼
    • 其他
  • 南美
    • 巴西
    • 墨西哥
    • 秘魯
    • 阿根廷
    • 智利
    • 其他
  • 中東
    • 沙烏地阿拉伯
    • 伊朗
    • 阿拉伯聯合大公國(UAE)
    • 其他
  • 非洲
    • 南非
    • 辛巴威
    • 阿爾及利亞
    • 其他
  • 大洋洲、其他地區

第13章 企業簡介

  • Abbott Laboratories
  • BGI Group
  • Becton, Dickinson and Company
  • BioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • CENTOGENE Holding AG
  • Cellex Inc.
  • CTK Biotech
  • Danaher Corporation
  • DiaSorin S.p.A
  • F. Hoffmann-La Roche Ltd
  • Hologic, Inc.
  • GenMark Diagnostics
  • PerkinElmer Inc.
  • QIAGEN N.V.
  • Quidel Corporation
  • Luminex Corporation
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
目錄
Product Code: BHP0959SA

"Global COVID-19 Diagnostic Testing Market to Reach $35.64 Billion by 4Q2021."

Market Report Coverage - COVID-19 Diagnostic Testing

Market Segmentation

  • Product - Kits and Assays, and Instruments
  • Sample Type - Swabs, Blood Samples, Urine Samples, and Other Samples
  • Technology - Molecular Assays and Immunoassays
  • End User - Hospitals and Healthcare Centers, Diagnostic Centers and Clinics, Research Institutions, and Other End Users

Regional Segmentation

  • North America - U.S., Canada, and Rest-of-North America
  • Europe - Germany, U.K., France, Italy, Spain, Russia, Netherlands and Rest-of-Europe
  • Asia-Pacific - China, India, Japan, Taiwan, South Korea, Singapore, Australia, Bangladesh, Pakistan, Indonesia, and Rest-of-Asia-Pacific
  • Latin America - Brazil, Mexico, Peru, Argentina, Chile, and Rest-of-Latin America
  • Middle East - Kingdom of Saudi Arabia (KSA), Iran, United Arab Emirates (UAE), and Rest-of-Middle East
  • Africa - South Africa, Zimbabwe, Algeria, and Rest-of-Africa
  • Oceania/Rest-of-the-World

Growth Drivers

  • Rising Cases of COVID-19 Globally, Inciting the Development of Diagnostic Tests
  • Technological Innovation Resulting in Market Pull
  • Significant External Funding Supporting Market Growth
  • Favourable Regulatory Scenario Aiding Companies to Launch COVID-19 Diagnostic Testing Products

Market Challenges

  • Less Efficiency of Rapid COVID-19 Diagnostic Testing as Compared with that of Laboratory Testing
  • Shortage of Skilled Professionals and Trained Lab-Technicians
  • Shortage of COVID-19 Diagnostic Test Reagents
  • Significant Dampening of the Market due to the Expected Launch of COVID-19 Vaccine

Market Opportunities

  • Massive Scope for Adoption of COVID-19 Point-of-Care (POC) Testing Products in Emerging Nations

Key Companies Profiled

Abbott Laboratories, BGI Group, Becton, Dickinson and Company, bioMerieux SA, Bio-Rad Laboratories, Inc., CENTOGENE Holding AG, Cellex Inc., CTK Biotech, Danaher Corporation, DiaSorin S.p.A, F. Hoffmann-La Roche Ltd, Hologic Inc., GenMark Diagnostics, PerkinElmer Inc., QIAGEN N.V., Luminex Corporation, Siemens Healthineers AG, and Thermo Fisher Scientific Inc.

Key Questions Answered in this Report:

  • What are the major market drivers, challenges, and opportunities in the global COVID-19 diagnostic testing market?
  • What are the underlying structures resulting in the emerging trends within the global COVID-19 diagnostic testing market?
  • How the COVID-19 pandemic impacted the global healthcare system?
  • What are the key development strategies which are being implemented by the major players in order to sustain in the competitive market?
  • What are the key regulatory implications in developed and developing regions for COVID-19 diagnostic testing?
  • What is the reimbursement scenario for the global COVID-19 diagnostic testing market?
  • How each segment of the market is expected to grow during the forecast period from 3Q2020 to 4Q2021 and what is the anticipated revenue to be generated by each of the segments on the basis of:
    • Product Type (Kits and Assays, and Instruments)
    • Sample Type (Swabs, Blood Samples, Urine Samples, and Others)
    • Technology (Molecular Assays, and Immunoassays)
    • End User (Hospitals and Healthcare Centers, Diagnostic Centers and Clinics, Research Institutions, and Others)
    • Region, including North America, Europe, Asia-Pacific, Latin America, Middle East, Africa, and Oceania/Rest-of-the-World
  • Who are the leading players with significant offerings to the global COVID-19 diagnostic testing market? What is the expected market dominance for each of these leading players?
  • Which companies are anticipated to be highly disruptive in the future and why?
  • What are the major strategies adopted by the countries for COVID-19 diagnostic testing?
  • What are the current unmet needs that are being faced?

Market Overview

Our healthcare experts have found COVID-19 Diagnostic Testing industry to be one of the most rapidly evolving and dynamic markets and the global market for COVID-19 diagnostic testing is predicted to grow at a CQGR of 23.50% over the forecast period of 3Q2020-4Q2021. The market is driven by certain factors, which include rising cases of COVID-19 globally, inciting the development of diagnostic tests, technological innovation resulting in market pull, significant external funding supporting market growth, and favourable regulatory scenario aiding companies to launch COVID-19 diagnostic testing products.

The market is favoured by the developments in the field of COVID-19 diagnostic testing solutions, particularly kits and assays, which are being developed by the emerging and the legacy diagnostic companies worldwide. Currently, the COVID-19 diagnostic testing industry is witnessing upsurge on account of growing number of cases worldwide coupled with the massive issuance of emergency use authorizations (EUAs) from the regulatory bodies to the manufacturers.

Furthermore, several diagnostic companies are focusing on the development of point-of-care (POC) rapid COVID-19 diagnostics tests having higher sensitivity and low turn-around time to benefit the patients, further providing provisions for the healthcare professions to offer treatment modalities.

Within the research report, the market is segmented on the basis of product type, sample type, technology, end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the number of COVID-19 cases on the global level has created a buzz among the diagnostic companies to invest in the development of efficient and rapid diagnostic testing solutions. Due to the diverse product and pipeline portfolio and intense market penetration, Abbott Laboratories has been a pioneer in this field and been a significant competitor in this market.

Several other companies such as Danaher Corporation, PerkinElmer Inc., and F. Hoffmann-La Roche Ltd, have also launched their respective COVID-19 diagnostic testing products, such as Xpert Xpress SARS-CoV-2, PerkinElmer SARS-CoV-2 Real-time RT-PCR Assay, and Cobas SARS-CoV-2 Test respectively, to compete with Abbott's market dominance.

On the basis of region, Asia-Pacific (APAC) holds the largest share of the COVID-19 diagnostic testing market and is anticipated to grow at the fastest CQGR during the forecast period, 3Q2020-4Q2021. Growing number of COVID-19 cases, growing emphasis in the development of novel diagnostic technologies, and rising healthcare awareness, among others, are some of the factors attributable to its largest share in the market.

Table of Contents

Executive Summary

1 Product Definition

  • 1.1 Inclusion and Exclusion

2 Research Scope

  • 2.1 Scope of the Study
  • 2.2 Key Questions Answered in the Report

3 Research Methodology

  • 3.1 COVID-19 Diagnostic Testing: Research Methodology
  • 3.2 Data Sources
    • 3.2.1 Primary Data Sources
    • 3.2.2 Secondary Data Sources
  • 3.3 Market Estimation Model

4 Market Overview

  • 4.1 Market Definition
  • 4.2 Impact of COVID-19 on Human Health
  • 4.3 Implications of COVID-19 on the Healthcare Sector
  • 4.4 Market Footprint and Growth Potential, Value ($Million), 2020-2021

5 Industry Insights

  • 5.1 Overview
  • 5.2 Legal Requirements and Framework in the U.S.
    • 5.2.1 Emergency Use Authorization (EUA)
  • 5.3 Legal Requirements and Framework in Europe
  • 5.4 Legal Requirement and Framework in the Asia-Pacific Region
    • 5.4.1 China
    • 5.4.2 Japan

6 Market Dynamics

  • 6.1 Overview
  • 6.2 Impact Analysis
  • 6.3 Drivers
    • 6.3.1 Rising Cases of COVID-19 Globally, Inciting the Development of Diagnostic Tests
    • 6.3.2 Technological Innovation Resulting in Market Pull
    • 6.3.3 Significant External Funding Supporting Market Growth
    • 6.3.4 Favorable Regulatory Scenario Aiding Companies to Launch COVID-19 Diagnostic Testing Products
  • 6.4 Restraints
    • 6.4.1 Less Efficient Rapid COVID-19 Diagnostic Testing as Compared to Laboratory Testing
    • 6.4.2 Shortage of Skilled Professionals and Trained Lab-Technicians
    • 6.4.3 Shortage of COVID-19 Diagnostic Test Reagents
    • 6.4.4 Significant Dampening of the Market Due to the Expected Launch of COVID-19 Vaccine
    • 6.4.5 Massive Scope for Adoption of COVID-19 Point-of-Care (POC) Testing Products in Emerging Nations

7 Competitive Landscape

  • 7.1 Key Strategies and Developments
    • 7.1.1 Product Approvals
    • 7.1.2 Synergistic Activities
    • 7.1.3 Product Launch and Upgradations
    • 7.1.4 Business Expansion and Funding
  • 7.2 Market Share Analysis

8 Global COVID-19 Diagnostic Testing Market (by Product)

  • 8.1 Overview
  • 8.2 Kits and Assays
  • 8.3 Instruments

9 Global COVID-19 Diagnostic Testing Market (by Sample Type)

  • 9.1 Overview
  • 9.2 Swabs
    • 9.2.1 Nasopharyngeal Swabs
    • 9.2.2 Oropharyngeal Swabs
  • 9.3 Blood Samples
  • 9.4 Urine Samples
  • 9.5 Other Samples

10 Global COVID-19 Diagnostic Testing Market (by Technology)

  • 10.1 Overview
  • 10.2 Molecular Assays
    • 10.2.1 Polymerase Chain Reaction (PCR)
      • 10.2.1.1 Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
      • 10.2.1.2 Droplet Digital Polymerase Chain Reaction (ddPCR)
    • 10.2.2 Isothermal Amplification
    • 10.2.3 Others
  • 10.3 Immunoassays
    • 10.3.1 Lateral Flow Immunoassay (LFIA)
    • 10.3.2 Enzyme Immunoassay (EIA)

11 Global COVID-19 Diagnostic Testing Market (by End User)

  • 11.1 Overview
  • 11.2 Hospitals and Healthcare Centers
  • 11.3 Diagnostic Centers and Clinics
  • 11.4 Research Institutions
  • 11.5 Other End Users

12 Global COVID-19 Diagnostic Testing Market (by Region)

  • 12.1 Overview
  • 12.2 North America
    • 12.2.1 U.S.
      • 12.2.1.1 Strategies Adopted by the U.S. for COVID-19 Diagnostic Testing
      • 12.2.1.2 U.S. COVID-19 Diagnostic Testing Market (by Technology)
        • 12.2.1.2.1 Molecular Assays
        • 12.2.1.2.2 Immunoassay
    • 12.2.2 Canada
      • 12.2.2.1 Strategies Adopted by Canada for COVID-19 Diagnostic Testing
      • 12.2.2.2 Canada COVID-19 Diagnostic Testing Market (by Technology)
        • 12.2.2.2.1 Molecular Assays
        • 12.2.2.2.2 Immunoassays
    • 12.2.3 Rest-of-North America
      • 12.2.3.1 Rest-of-North America COVID-19 Diagnostic Testing Market (by Technology)
        • 12.2.3.1.1 Molecular Assays
        • 12.2.3.1.2 Immunoassays
  • 12.3 Europe
    • 12.3.1 Germany
      • 12.3.1.1 Strategies Adopted by Germany for COVID-19 Diagnostic Testing
      • 12.3.1.2 Germany COVID-19 Diagnostic Testing Market (by Technology)
        • 12.3.1.2.1 Molecular Assays
        • 12.3.1.2.2 Immunoassays
    • 12.3.2 U.K.
      • 12.3.2.1 Strategies Adopted by the U.K. for COVID-19 Diagnostic Testing
      • 12.3.2.2 U.K. COVID-19 Diagnostic Testing Market (by Technology)
        • 12.3.2.2.1 Molecular Assays
        • 12.3.2.2.2 Immunoassays
    • 12.3.3 France
      • 12.3.3.1 Strategies Adopted by France for COVID-19 Diagnostic Testing
      • 12.3.3.2 France COVID-19 Diagnostic Testing Market (by Technology)
        • 12.3.3.2.1 Molecular Assays
        • 12.3.3.2.2 Immunoassays
    • 12.3.4 Italy
      • 12.3.4.1 Strategies Adopted by Italy for COVID-19 Diagnostic Testing
      • 12.3.4.2 Italy COVID-19 Diagnostic Testing Market (by Technology)
        • 12.3.4.2.1 Molecular Assays
        • 12.3.4.2.2 Immunoassays
    • 12.3.5 Spain
      • 12.3.5.1 Strategies Adopted by Spain for COVID-19 Diagnostic Testing
      • 12.3.5.2 Spain COVID-19 Diagnostic Testing Market (by Technology)
        • 12.3.5.2.1 Molecular Assays
        • 12.3.5.2.2 Immunoassays
    • 12.3.6 Russia
      • 12.3.6.1 Russia COVID-19 Diagnostic Testing Market (by Technology)
        • 12.3.6.1.1 Molecular Assays
        • 12.3.6.1.2 Immunoassays
    • 12.3.7 Netherlands
      • 12.3.7.1 Strategies Adopted by Netherlands for COVID-19 Diagnostic Testing
      • 12.3.7.2 Netherlands COVID-19 Diagnostic Testing Market (by Technology)
        • 12.3.7.2.1 Molecular Assays
        • 12.3.7.2.2 Immunoassays
    • 12.3.8 Rest-of-Europe
      • 12.3.8.1 Rest-of-Europe COVID-19 Diagnostic Testing Market (by Technology)
        • 12.3.8.1.1 Molecular Assays
        • 12.3.8.1.2 Immunoassays
  • 12.4 Asia-Pacific
    • 12.4.1 China
      • 12.4.1.1 Strategies Adopted by China for COVID-19 Diagnostic Testing
      • 12.4.1.2 China COVID-19 Diagnostic Testing Market (by Technology)
        • 12.4.1.2.1 Molecular Assays
        • 12.4.1.2.2 Immunoassays
    • 12.4.2 India
      • 12.4.2.1 Strategies Adopted by India for COVID-19 Diagnostic Testing
      • 12.4.2.2 India COVID-19 Diagnostic Testing Market (by Technology)
        • 12.4.2.2.1 Molecular Assays
        • 12.4.2.2.2 Immunoassays
    • 12.4.3 Japan
      • 12.4.3.1 Strategies Adopted by Japan for COVID-19 Diagnostic Testing
      • 12.4.3.2 Japan COVID-19 Diagnostic Testing Market (by Technology)
        • 12.4.3.2.1 Molecular Assays
        • 12.4.3.2.2 Immunoassays
    • 12.4.4 Taiwan
      • 12.4.4.1 Strategies Adopted by Taiwan for COVID-19 Diagnostic Testing
      • 12.4.4.2 Taiwan COVID-19 Diagnostic Testing Market (by Technology)
        • 12.4.4.2.1 Molecular Assays
        • 12.4.4.2.2 Immunoassays
    • 12.4.5 South Korea
      • 12.4.5.1 Strategies Adopted by South Korea for COVID-19 Diagnostic Testing
      • 12.4.5.2 South Korea COVID-19 Diagnostic Testing Market (by Technology)
        • 12.4.5.2.1 Molecular Assays
        • 12.4.5.2.2 Immunoassays
    • 12.4.6 Singapore
      • 12.4.6.1 Strategies Adopted by Singapore for COVID-19 Diagnostic Testing
      • 12.4.6.2 Singapore COVID-19 Diagnostic Testing Market (by Technology)
        • 12.4.6.2.1 Molecular Assays
        • 12.4.6.2.2 Immunoassays
    • 12.4.7 Australia
      • 12.4.7.1 Strategies Adopted by Australia for COVID-19 Diagnostic Testing
      • 12.4.7.2 Australia COVID-19 Diagnostic Testing Market (by Technology)
        • 12.4.7.2.1 Molecular Assays
        • 12.4.7.2.2 Immunoassays
    • 12.4.8 Bangladesh
      • 12.4.8.1 Strategies Adopted by Bangladesh for COVID-19 Diagnostic Testing
      • 12.4.8.2 Bangladesh COVID-19 Diagnostic Testing Market (by Technology)
        • 12.4.8.2.1 Molecular Assays
        • 12.4.8.2.2 Immunoassays
    • 12.4.9 Pakistan
      • 12.4.9.1 Strategies Adopted by Pakistan for COVID-19 Diagnostic Testing
      • 12.4.9.2 Pakistan COVID-19 Diagnostic Testing Market (by Technology)
        • 12.4.9.2.1 Molecular Assays
        • 12.4.9.2.2 Immunoassays
    • 12.4.10 Indonesia
      • 12.4.10.1 Strategies Adopted by Indonesia for COVID-19 Diagnostic Testing
      • 12.4.10.2 Indonesia COVID-19 Diagnostic Testing Market (by Technology)
        • 12.4.10.2.1 Molecular Assays
        • 12.4.10.2.2 Immunoassays
    • 12.4.11 Rest-of-APAC(RoAPAC)
      • 12.4.11.1 Rest-of-APAC COVID-19 Diagnostic Testing Market (by Technology)
        • 12.4.11.1.1 Molecular Assays
        • 12.4.11.1.2 Immunoassays
  • 12.5 Latin America
    • 12.5.1 Brazil
      • 12.5.1.1 Strategies Adopted by Brazil for COVID-19 Diagnostic Testing
      • 12.5.1.2 Brazil COVID-19 Diagnostic Testing Market (by Technology)
        • 12.5.1.2.1 Molecular Assays
        • 12.5.1.2.2 Immunoassays
    • 12.5.2 Mexico
      • 12.5.2.1 Strategies Adopted by Mexico for COVID-19 Diagnostic Testing
      • 12.5.2.2 Mexico COVID-19 Diagnostic Testing Market (by Technology)
        • 12.5.2.2.1 Molecular Assays
        • 12.5.2.2.2 Immunoassays
    • 12.5.3 Peru
      • 12.5.3.1 Strategies Adopted by Peru for COVID-19 Diagnostic Testing
      • 12.5.3.2 Peru COVID-19 Diagnostic Testing Market (by Technology)
        • 12.5.3.2.1 Molecular Assays
        • 12.5.3.2.2 Immunoassays
    • 12.5.4 Argentina
      • 12.5.4.1 Strategies Adopted by Argentina for COVID-19 Diagnostic Testing
      • 12.5.4.2 Argentina COVID-19 Diagnostic Testing Market (by Technology)
        • 12.5.4.2.1 Molecular Assays
        • 12.5.4.2.2 Immunoassays
    • 12.5.5 Chile
      • 12.5.5.1 Strategies Adopted by Chile for COVID-19 Diagnostic Testing
      • 12.5.5.2 Chile COVID-19 Diagnostic Testing Market (by Technology)
        • 12.5.5.2.1 Molecular Assays
        • 12.5.5.2.2 Immunoassays
    • 12.5.6 Rest-of-Latin America (RoLA)
      • 12.5.6.1 Rest-of-Latin America COVID-19 Diagnostic Testing Market (by Technology)
        • 12.5.6.1.1 Molecular Assays
        • 12.5.6.1.2 Immunoassays
  • 12.6 Middle East
    • 12.6.1 Kingdom of Saudi Arabia
      • 12.6.1.1 Strategies Adopted by KSA for COVID-19 Diagnostic Testing
      • 12.6.1.2 KSA COVID-19 Diagnostic Testing Market (by Technology)
        • 12.6.1.2.1 Molecular Assays
        • 12.6.1.2.2 Immunoassays
    • 12.6.2 Iran
      • 12.6.2.1 Strategies Adopted by Iran for COVID-19 Diagnostic Testing
      • 12.6.2.2 Iran COVID-19 Diagnostic Testing Market (by Technology)
        • 12.6.2.2.1 Molecular Assays
        • 12.6.2.2.2 Immunoassays
    • 12.6.3 United Arab Emirates (U.A.E.)
      • 12.6.3.1 U.A.E. COVID-19 Diagnostic Testing Market (by Technology)
        • 12.6.3.1.1 Molecular Assays
        • 12.6.3.1.2 Immunoassays
    • 12.6.4 Rest-of-Middle East
      • 12.6.4.1 Rest-of-Middle East COVID-19 Diagnostic Testing Market (by Technology)
        • 12.6.4.1.1 Molecular Assays
        • 12.6.4.1.2 Immunoassays
  • 12.7 Africa
    • 12.7.1 South Africa
      • 12.7.1.1 Strategies Adopted by South Africa for COVID-19 Diagnostic Testing
      • 12.7.1.2 South Africa COVID-19 Diagnostic Testing Market (by Technology)
        • 12.7.1.2.1 Molecular Assays
        • 12.7.1.2.2 Immunoassays
    • 12.7.2 Zimbabwe
      • 12.7.2.1 Zimbabwe COVID-19 Diagnostic Testing Market (by Technology)
        • 12.7.2.1.1 Molecular Assays
        • 12.7.2.1.2 Immunoassays
    • 12.7.3 Algeria
      • 12.7.3.1 Algeria COVID-19 Diagnostic Testing Market (by Technology)
        • 12.7.3.1.1 Molecular Assays
        • 12.7.3.1.2 Immunoassays
    • 12.7.4 Rest-of-Africa
      • 12.7.4.1 Rest-of-Africa COVID-19 Diagnostic Testing Market (by Technology)
        • 12.7.4.1.1 Molecular Assays
        • 12.7.4.1.2 Immunoassays
  • 12.8 Oceania/Rest-of-the-World
    • 12.8.1 Oceania/RoW COVID-19 Diagnostic Testing Market (by Technology)
    • 12.8.2 Molecular Assays
    • 12.8.3 Immunoassays

13 Company Profiles

  • 13.1 Overview
  • 13.2 Abbott Laboratories
    • 13.2.1 Company Overview
    • 13.2.2 BIS Insights
  • 13.3 BGI Group
    • 13.3.1 Company Overview
    • 13.3.2 BIS Insights
  • 13.4 Becton, Dickinson and Company
    • 13.4.1 Company Overview
    • 13.4.2 BIS Insights
  • 13.5 BioMerieux SA
    • 13.5.1 Company Overview
    • 13.5.2 BIS Insights
  • 13.6 Bio-Rad Laboratories, Inc.
    • 13.6.1 Company Overview
    • 13.6.2 BIS Insights
  • 13.7 CENTOGENE Holding AG
    • 13.7.1 Company Overview
    • 13.7.2 BIS Insights
  • 13.8 Cellex Inc.
    • 13.8.1 Company Overview
    • 13.8.2 BIS Insights
  • 13.9 CTK Biotech
    • 13.9.1 Company Overview
    • 13.9.2 BIS Insights
  • 13.1 Danaher Corporation
    • 13.10.1 Company Overview
    • 13.10.2 BIS Insights
  • 13.11 DiaSorin S.p.A
    • 13.11.1 Company Overview
    • 13.11.2 BIS Insights
  • 13.12 F. Hoffmann-La Roche Ltd
    • 13.12.1 Company Overview
    • 13.12.2 BIS Insights
  • 13.13 Hologic, Inc.
    • 13.13.1 Company Overview
    • 13.13.2 BIS Insights
  • 13.14 GenMark Diagnostics
    • 13.14.1 Company Overview
    • 13.14.2 BIS Insights
  • 13.15 PerkinElmer Inc.
    • 13.15.1 Company Overview
    • 13.15.2 BIS Insights
  • 13.16 QIAGEN N.V.
    • 13.16.1 Company Overview
    • 13.16.2 BIS Insights
  • 13.17 Quidel Corporation
    • 13.17.1 Company Overview
    • 13.17.2 BIS Insights
  • 13.18 Luminex Corporation
    • 13.18.1 Company Overview
    • 13.18.2 BIS Insights
  • 13.19 Siemens Healthineers AG
    • 13.19.1 Company Overview
    • 13.19.2 BIS Insights
  • 13.2 Thermo Fisher Scientific Inc.
    • 13.20.1 Company Overview
    • 13.20.2 BIS Insights

List of Figures

  • Figure 1: Global COVID-19 Cumulative Cases
  • Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global COVID-19 Diagnostic Testing Market
  • Figure 3: Global COVID-19 Diagnostic Testing Market (by Product), Value ($Million), 2Q2020-4Q2021
  • Figure 4: Global COVID-19 Diagnostic Testing Market (by Sample Type), Value ($Million), 2Q2020-4Q2021
  • Figure 5: Global COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 2Q2020-4Q2021
  • Figure 6: Global COVID-19 Diagnostic Testing Market (by End User), Value ($Million), 2Q2020-4Q2021
  • Figure 7: Global COVID-19 Diagnostic Testing Market (by Region), Value ($Million), 2Q2020-4Q2021
  • Figure 2.1: Global COVID-19 Diagnostic Testing Market Segmentation
  • Figure 3.1: Global COVID-19 Diagnostic Testing Market: Research Methodology
  • Figure 3.2: Primary Research Methodology
  • Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
  • Figure 4.1: Implications of COVID-19 on the Healthcare Sector: Short- and Long-Term Analysis
  • Figure 4.2: Global COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020 and 4Q2021
  • Figure 5.1: Procedure for Obtaining Emergency Use Authorization (EUA)
  • Figure 5.2: Components Considered for Clinical Evidence as per the IVDR
  • Figure 5.3: Procedure for IVD Medical Device Registration in China
  • Figure 6.1: Number of COVID-19 Confirmed Cases, Globally
  • Figure 7.1: Share of Key Developments and Strategies, January 2020 - July 2020
  • Figure 7.2: Product Approval Share (by Company), January 2020 - July 2020
  • Figure 7.3: Synergistic Activities Share (by Company), January 2020 - July 2020
  • Figure 7.4: Product Launch and Upgradations Share (by Company), January 2020 - July 2020
  • Figure 7.6: Market Share Analysis for Global COVID-19 Diagnostic Testing Market, 2Q2020
  • Figure 8.1: Global COVID-19 Diagnostic Testing Market (by Product Type)
  • Figure 8.2: Global COVID-19 Diagnostic Testing Market (by Product Type), 2Q2020 and 4Q2021
  • Figure 8.3: Global COVID-19 Diagnostic Testing Market (for Kits and Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 8.4: Global COVID-19 Diagnostic Testing Market (for Instruments), Value ($Million), 1Q2020-4Q2021
  • Figure 9.1: Global COVID-19 Diagnostic Testing Market (by Sample Type)
  • Figure 9.2: Global COVID-19 Diagnostic Testing Market (by Sample Type), 2Q2020-4Q2021
  • Figure 9.3: Global COVID-19 Diagnostic Testing Market (by Swab), 2Q2020 and 4Q2021
  • Figure 9.4: Global COVID-19 Diagnostic Testing Market (for Nasopharyngeal Swabs), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 9.5: Global COVID-19 Diagnostic Testing Market (for Nasopharyngeal Swabs), Value ($Million), 1Q2020-4Q2021
  • Figure 9.6: Global COVID-19 Diagnostic Testing Market (for Oropharyngeal Swabs), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 9.7: Global COVID-19 Diagnostic Testing Market (for Oropharyngeal Swabs), Value ($Million), 1Q2020-4Q2021
  • Figure 9.8: Global COVID-19 Diagnostic Testing Market (for Blood Samples), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 9.9: Global COVID-19 Diagnostic Testing Market (for Blood Samples), Value ($Million), 1Q2020-4Q2021
  • Figure 9.10: Global COVID-19 Diagnostic Testing Market (for Urine Samples), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 9.11: Global COVID-19 Diagnostic Testing Market (for Urine Samples), Value ($Million), 1Q2020-4Q2021
  • Figure 9.12: Global COVID-19 Diagnostic Testing Market (for Other Samples), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 9.13: Global COVID-19 Diagnostic Testing Market (for Other Samples), Value ($Million), 1Q2020-4Q2021
  • Figure 10.1: Global COVID-19 Diagnostic Testing Market (by Technology)
  • Figure 10.2: Global COVID-19 Diagnostic Testing Market (by Technology), 2Q2020-4Q2021
  • Figure 10.3: Global COVID-19 Diagnostic Testing Market (by Molecular Assays), 2Q2020 and 4Q2021
  • Figure 10.4: Global COVID-19 Diagnostic Testing Market (for PCR), Value ($Million), 1Q2020-4Q2021
  • Figure 10.5: Global COVID-19 Diagnostic Testing Market (for RT-PCR), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 10.6: Global COVID-19 Diagnostic Testing Market (for RT-PCR), Value ($Million), 1Q2020-4Q2021
  • Figure 10.7: Global COVID-19 Diagnostic Testing Market (for ddPCR), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 10.8: Global COVID-19 Diagnostic Testing Market (for ddPCR), Value ($Million), 1Q2020-4Q2021
  • Figure 10.9: Global COVID-19 Diagnostic Testing Market (for Isothermal Amplification), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 10.10: Global COVID-19 Diagnostic Testing Market (for Isothermal Amplification), Value ($Million), 1Q2020-4Q2021
  • Figure 10.11: Global COVID-19 Diagnostic Testing Market (for Others), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 10.12: Global COVID-19 Diagnostic Testing Market (for Others), Value ($Million), 1Q2020-4Q2021
  • Figure 10.13: Global COVID-19 Diagnostic Testing Market (by Immunoassays), 2Q2020 and 4Q2021
  • Figure 10.14: Global COVID-19 Diagnostic Testing Market (for Later Flow Immunoassay), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 10.15: Global COVID-19 Diagnostic Testing Market (for Later Flow Immunoassay), Value ($Million), 1Q2020-4Q2021
  • Figure 10.16: Global COVID-19 Diagnostic Testing Market (for Enzyme Immunoassay), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 10.17: Global COVID-19 Diagnostic Testing Market (for Enzyme Immunoassay), Value ($Million), 1Q2020-4Q2021
  • Figure 11.1: Global COVID-19 Diagnostic Testing Market (by End User)
  • Figure 11.2: Global COVID-19 Diagnostic Testing Market (by End User), 2Q2020-4Q2021
  • Figure 11.3: Global COVID-19 Diagnostic Testing Market (for Hospitals and Healthcare Centers), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 11.4: Global COVID-19 Diagnostic Testing Market (for Hospitals and Healthcare Centers), Value ($Million), 1Q2020-4Q2021
  • Figure 11.5: Global COVID-19 Diagnostic Testing Market (for Diagnostic Centers and Clinics), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 11.6: Global COVID-19 Diagnostic Testing Market (for Diagnostic Centers and Clinics), Value ($Million), 1Q 2020-4Q2021
  • Figure 11.7: Global COVID-19 Diagnostic Testing Market (for Research Institutions), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 11.8: Global COVID-19 Diagnostic Testing Market (for Research Institutions), Value ($Million), 1Q2020-4Q2021
  • Figure 11.9: Global COVID-19 Diagnostic Testing Market (for Other End Users), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 11.10: Global COVID-19 Diagnostic Testing Market (for Other End Users), Value ($Million), 1Q2020-4Q2021
  • Figure 12.1: Global COVID-19 Diagnostic Testing Market (by Region)
  • Figure 12.2: Global COVID-19 Diagnostic Testing Market (by Region), Value ($Million), 1Q2020-4Q2021
  • Figure 12.3: Global COVID-19 Diagnostic Testing Market (by Region), 1Q2020 and 4Q2021
  • Figure 12.4: North America COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.5: North America COVID-19 Diagnostic Testing Market (by Country), Value ($Million), 1Q2020-4Q2021
  • Figure 12.6: North America: Market Dynamics
  • Figure 12.7: U.S. COVID-19 Diagnostic Testing Market, Value (Million), 1Q2020-4Q2021
  • Figure 12.8: U.S. Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.9: U.S. COVID-19 Diagnostic Testing Market (by Technology), 1Q2020-4Q2021
  • Figure 12.10: U.S. COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.11: U.S. COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), Q12020-4Q2021
  • Figure 12.12: U.S. COVID-19 Diagnostic Testing Market (for Immunoassay), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.13: U.S. COVID-19 Diagnostic Testing Market (for Immunoassay), Value ($Million), 2020-2021
  • Figure 12.14: Canada COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.15: Canada Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.16: Canada COVID-19 Diagnostic Testing Market (by Technology), 1Q2020-4Q2021
  • Figure 12.17: Canada COVID-19 Diagnostic Testing Market (for Molecular Assays, Volume (Thousand Units), Q12020-4Q2021
  • Figure 12.18: Canada COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.19: Canada COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), Q12020-Q42021
  • Figure 12.20: Canada COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.21: Rest-of-North America COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.22: Rest-of-North America COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.23: Rest-of-North America COVID-19 Diagnostic Testing Market (for Molecular Assays, Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.24: Rest-of-North America COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), Q12020-4Q2021
  • Figure 12.25: Rest-of-North America COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.26: Rest-of-North America COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.27: Europe COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.28: Europe: Market Dynamics
  • Figure 12.29: Europe COVID-19 Diagnostic Testing Market (by Country), Value ($Million), 1Q2020-4Q2021
  • Figure 12.30: Germany COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.31: Germany Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.32: Germany COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.33: Germany COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.34: Germany COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.35: Germany COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.36: Germany COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.37: U.K. COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.38: U.K. Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.39: U.K. COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.40: U.K. COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.41: U.K. COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.42: U.K. COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.43: U.K. COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.44: France COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.45: France Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.46: France COVID-19 Diagnostic Testing Market (by Technology), Value ($Million) 1Q2020-4Q2021
  • Figure 12.47: France COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.48: France COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.49: France COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.50: France COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.51: Italy COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.52: Italy Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.53: Italy COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.54: Italy COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.55: Italy COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.56: Italy COVID-19 Diagnostic Testing Market (for Immunoassay), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.57: Italy COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.58: Spain COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.59: Spain Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.60: Spain COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.61: Spain COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.62: Spain COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.63: Spain COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.64: Spain COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.65: Russia COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.66: Russia Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.67: Russia COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.68: Russia COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.69: Russia COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.70: Russia COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.71: Russia COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.72: Netherlands COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.73: Netherlands Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.74: Netherlands COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.75: Netherlands COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.76: Netherlands COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.77: Netherlands COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.78: Netherlands COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.79: Rest-of-Europe COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.80: Rest-of-Europe COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.81: Rest-of-Europe COVID-19 Diagnostic Testing Market (for Molecular Assays, Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.82: Rest-of-Europe COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), Q12020-4Q2021
  • Figure 12.83: Rest-of-Europe COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.84: Rest-of-Europe COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.85: Asia-Pacific COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.86: APAC: Market Dynamics
  • Figure 12.87: APAC COVID-19 Diagnostic Testing Market (by Country), Value ($Million), 1Q2020-4Q2021
  • Figure 12.88: China COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.89: China Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.90: China COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.91: The China COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.92: The China COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.93: China COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.94: China COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.95: India COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.96: India Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.97: India COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.98: India COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.99: India COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.100: India COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.101: India COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.102: Japan COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.103: Japan Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.104: Japan COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.105: Japan COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.106: Japan COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.107: Japan COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.108: Japan COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.109: Taiwan COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.110: Taiwan Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.111: Taiwan COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.112: Taiwan COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.113: Taiwan COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.114: Taiwan COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.115: Taiwan COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.116: South Korea COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.117: South Korea Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.118: South Korea COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.119: South Korea COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.120: South Korea COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.121: South Korea COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.122: South Korea COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.123: Singapore COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.124: Singapore Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.125: Singapore COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.126: Singapore COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.127: Singapore COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.128: Singapore COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.129: Singapore COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.130: Australia COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.131: Australia Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.132: Australia COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.133: Australia COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.134: Australia COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.135: Australia COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.136: Australia COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.137: Bangladesh COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.138: Bangladesh Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.139: Bangladesh COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.140: Bangladesh COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.141: Bangladesh COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.142: Bangladesh COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.143: Bangladesh COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.144: Pakistan COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.145: Pakistan Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.146: Pakistan COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.147: Pakistan COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.148: Pakistan COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.149: Pakistan COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.150: Pakistan COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.151: Indonesia COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.152: Indonesia Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.153: Indonesia COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.154: Indonesia COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume, 1Q2020-4Q2021
  • Figure 12.155: Indonesia COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.156: Indonesia COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.157: Indonesia COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.158: RoAPAC COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.159: Rest-of-APAC COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.160: Rest-of-APAC COVID-19 Diagnostic Testing Market (for Molecular Assays, Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.161: Rest-of-APAC COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), Q12020-4Q2021
  • Figure 12.162: Rest-of-APAC COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.163: Rest-of-APAC COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.164: Latin America COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.165: Latin America: Market Dynamics
  • Figure 12.166: Latin America COVID-19 Diagnostic Testing Market (by Country), Value ($Million), 1Q2020-4Q2021
  • Figure 12.167: Brazil COVID-19 Diagnostic Testing Market, Value ($Million), 3Q2020-4Q2021
  • Figure 12.168: Brazil Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.169: Brazil COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.170: Brazil COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.171: Brazil COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.172: Brazil COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.173: Brazil COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.174: Mexico COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.175: Mexico Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.176: Mexico COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.177: Mexico COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.178: Mexico COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.179: Mexico COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.180: Mexico COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.181: Peru COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.182: Peru Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.183: Peru COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.184: Peru COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.185: Peru COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.186: Peru COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.187: Peru COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.188: Argentina COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.189: Argentina Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.190: Argentina COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.191: Argentina COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.192: Argentina COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.193: Argentina COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.194: Argentina COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.195: Chile COVID-19 Diagnostic Testing Market, $Million, Q12020-Q42021
  • Figure 12.196: Chile Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.197: Chile COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.198: Chile COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.199: Chile COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.200: Chile COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.201: Chile COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.202: RoLA COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.203: Rest-of-Latin America COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.204: Rest-of-Latin America COVID-19 Diagnostic Testing Market (for Molecular Assays, Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.205: Rest-of-Latin America COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), Q12020-4Q2021
  • Figure 12.206: Rest-of-Latin America COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.207: Rest-of-Latin America COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.208: Middle East COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.209: Middle East: Market Dynamics
  • Figure 12.210: Middle East COVID-19 Diagnostic Testing Market (by Country), Value ($Million), 1Q2020-4Q2021
  • Figure 12.211: KSA COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.212: KSA Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.213: KSA COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.214: KSA COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.215: KSA COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.216: KSA COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.217: KSA COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.218: Iran COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.219: Iran Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.220: Iran COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.221: Iran COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.222: Iran COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.223: Iran COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.224: Iran COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.225: U.A.E. COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.226: U.A.E. Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.227: U.A.E. COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.228: U.A.E. COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.229: U.A.E. COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.230: U.A.E. COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.231: U.A.E. COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.232: Rest-of-Middle East COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.233: Rest-of-Middle East COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.234: Rest-of-Middle East COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.235: Rest-of-Middle East COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.236: Rest-of-Middle East COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.237: Rest-of-Middle East COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.238: Africa COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.239: Africa: Market Dynamics
  • Figure 12.240: Africa COVID-19 Diagnostic Testing Market (by Country), Value ($Million), 1Q2020-4Q2021
  • Figure 12.241: South Africa COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.242: South Africa Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.243: South Africa COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.244: South Africa COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.245: South Africa COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.246: South Africa COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.247: South Africa COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.248: Zimbabwe COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.249: Zimbabwe Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.250: Zimbabwe COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.251: Zimbabwe COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.252: Zimbabwe COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.253: Zimbabwe COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.254: Zimbabwe COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.255: Algeria COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.256: Algeria Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.257: Algeria COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.258: Algeria COVID-19 Diagnostic Testing Market (by Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.259: Algeria COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.260: Algeria COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.261: Algeria COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.262: Rest-of-Africa COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.263: Rest-of-Africa COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.264: Rest-of-Africa COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.265: Rest-of-Africa COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.266: Rest-of-Africa COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.267: Rest-of-Africa COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.268: Oceania/RoW COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.269: Oceania/RoW COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.270: Oceania/RoW COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.271: Oceania/RoW COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.272: Oceania/RoW COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.273: Oceania/RoW COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 13.1: Total Number of Companies Profiled
  • Figure 13.2: Competitive Benchmarking of Abbott Laboratories
  • Figure 13.3: Competitive Benchmarking of BGI Group
  • Figure 13.4: Competitive Benchmarking of Becton, Dickinson and Company
  • Figure 13.5: Competitive Benchmarking of BioMerieux SA
  • Figure 13.6: Competitive Benchmarking of Bio-Rad Laboratories, Inc.
  • Figure 13.7: Competitive Benchmarking of CENTOGENE Holding AG
  • Figure 13.8: Competitive Benchmarking of Cellex Inc.
  • Figure 13.9: Competitive Benchmarking of CTK Biotech
  • Figure 13.10: Competitive Benchmarking of Danaher Corporation
  • Figure 13.11: Competitive Benchmarking of DiaSorin S.p.A
  • Figure 13.12: Competitive Benchmarking of F. Hoffmann-La Roche Ltd
  • Figure 13.13: Competitive Benchmarking of Hologic, Inc.
  • Figure 13.14: Competitive Benchmarking of GenMark Diagnostics
  • Figure 13.15: Competitive Benchmarking of PerkinElmer Inc.
  • Figure 13.16: Competitive Benchmarking of QIAGEN N.V.
  • Figure 13.17: Competitive Benchmarking of Quidel Corporation
  • Figure 13.18: Competitive Benchmarking of Luminex Corporation
  • Figure 13.19: Competitive Benchmarking of Siemens Healthineers AG
  • Figure 13.20: Competitive Benchmarking of Thermo Fisher Scientific Inc.

List of Tables

  • Table 5.1: Registration Criteria for IVD Medical Devices as per the NMPA
  • Table 6.1: Impact Analysis of Market Drivers
  • Table 6.2: Impact Analysis of Market Restraints
  • Table 12.1: Key Players Offering Molecular Assays in the U.S.
  • Table 12.2: Key Players Offering Immunoassays in the U.S.
  • Table 12.3: Key Players Offering Molecular Assays in Canada
  • Table 12.4: Key Players Offering Immunoassays in Canada
  • Table 12.5: Key Players Offering Molecular Assays in Germany
  • Table 12.6: Key Players Offering Immunoassays in Germany
  • Table 12.7: Key Players Offering Molecular Assays in the U.K.
  • Table 12.8: Key Players Offering Immunoassays in the U.K.
  • Table 12.9: Key Players Offering Molecular Assays in France
  • Table 12.10: Key Players Offering Molecular Assays in France
  • Table 12.11: Key Players Offering Molecular Assays in Italy
  • Table 12.12: Key Players Offering Immunoassays in Italy
  • Table 12.13: Key Players Offering Molecular Assays in Spain
  • Table 12.14: Key Players Offering Immunoassays in Spain
  • Table 12.15: Key Players Offering Molecular Assays in Netherlands
  • Table 12.17: Key Players Offering Molecular Assays in China
  • Table 12.18: Key Players Offering Immunoassays in China
  • Table 12.19: Key Players Offering Molecular Assays in India
  • Table 12.20: Key Players Offering Immunoassays in India
  • Table 12.21: Key Players Offering Molecular Assays in Japan
  • Table 12.22: Key Players Offering Immunoassays in Japan
  • Table 12.23: Key Players Offering Molecular Assays in Taiwan
  • Table 12.24: Key Players Offering Molecular Assays in South Korea
  • Table 12.25: Key Players Offering Immunoassays in South Korea
  • Table 12.26: Key Players Offering Molecular Assays in Singapore
  • Table 12.27: Key Players Offering Immunoassays in Singapore
  • Table 12.28: Key Players Offering Molecular Assays in Australia
  • Table 12.29: Key Players Offering Immunoassays in Australia